Hyperlipidemia as a risk factor for discontinuation of prescribed antimuscarinics among geriatric overactive bladder patients

LUTS: Lower Urinary Tract Symptoms, Volume 11, Issue 4, Page 255-256, September 2019.
Source: LUTS: Lower Urinary Tract Symptoms - Category: Urology & Nephrology Authors: Tags: LETTER TO THE EDITOR Source Type: research

Related Links:

Publication date: Available online 18 October 2019Source: Life SciencesAuthor(s): Biljana Musicki, Uzoma A. Anele, Jeffrey D. Campbell, Serkan Karakus, Sruti Shiva, Fabio H. Silva, Arthur L. BurnettAbstractAimsNitric oxide (NO) has a critical, but not well understood, influence in the physiology of the lower urinary tract. We evaluated the effect of NO/phosphodiesterase (PDE)5 signaling in voiding dysfunction in the sickle cell disease (SCD) mouse, characterized by low NO bioavailability.Main methodsAdult SCD (Sickle) and wild-type (WT) male mice were treated daily with sodium nitrate (10 mM) or vehicle. After 18 days, b...
Source: Life Sciences - Category: Biology Source Type: research
Authors: Elbaset MA, Taha DE, El-Hefnawy AS, Zahran MH, Shokeir AA Abstract PURPOSE: To evaluate the efficacy and safety of re-treatment with anticholinergics on refractory idiopathic overactive bladder (OAB) previously treated with intravesical botulinum neurotoxin type A (BTX-A) injections. METHODS: One hundred patients were initially managed by intravesical injections of 100 IU of BTX-A. After the effects of BTX-A faded, patients were randomized into 2 groups: group A patients received solifenacin (10 mg) for 12 weeks (study group), while group B patients received placebo treatment for 12 weeks (control grou...
Source: International Neurourology Journal - Category: Urology & Nephrology Tags: Int Neurourol J Source Type: research
CONCLUSION: BTXA appears effective for OAB refractory to SNM, although the success rate is lower compared to BTXA patients without SNM exposure. PMID: 31607102 [PubMed]
Source: International Neurourology Journal - Category: Urology & Nephrology Tags: Int Neurourol J Source Type: research
CONCLUSION: DO is almost universal in all patients with PD complaining of OAB symptoms (97.1%). However, a significant percentage of patients also had BOO (36.8%), DU (47%), and increased PVR (16.7%) indicating that neurogenic DO may not be the only cause of OAB symptoms in PD patients. PMID: 31607100 [PubMed]
Source: International Neurourology Journal - Category: Urology & Nephrology Tags: Int Neurourol J Source Type: research
Publication date: November–December 2019Source: Journal of Minimally Invasive Gynecology, Volume 26, Issue 7, SupplementAuthor(s): L Zhu, Y ZhangStudy ObjectiveTo evaluate the long-term safety and effectiveness of inside–out transobturator tape (tension-free vaginal tape-obturator, TVT-O) for the treatment of stress urinary incontinence (SUI).DesignA prospective cohort study. The duration of follow-up was 12years.SettingCenter of obstetrics and gynecology in a tertiary-care hospital.Patients or ParticipantsBetween August 2004 and August 2006, 87 consecutive patients with SUI who underwent TVT-O were enrolled in...
Source: Journal of Minimally Invasive Gynecology - Category: OBGYN Source Type: research
To ascertain whether a poor response and adverse events (voiding dysfunction and urinary tract infection) were predictable for first time botulinum toxin-A (BTX-A) injections in a patient cohort of refractory idiopathic overactive bladder (OAB) with detrusor overactivity (DO).
Source: Urology - Category: Urology & Nephrology Authors: Tags: Original Article Source Type: research
Conclusions: Pretreatment with trospium 60 mg ER reduces the incidence and severity of CRBD in the early postoperative period. PMID: 31602966 [PubMed - as supplied by publisher]
Source: Korean Journal of Anesthesiology - Category: Anesthesiology Tags: Korean J Anesthesiol Source Type: research
Medtronic has filed for FDA approval for its InterStim Micro neurostimulator and the accompanying InterStim SureScan MRI leads. The rechargeable device delivers sacral neuromodulation therapy to treat conditions such as overactive bladder, fecal inco...
Source: Medgadget - Category: Medical Devices Authors: Tags: Neurology Neurosurgery Radiology Rehab Source Type: blogs
Publication date: October 2019Source: European Urology Supplements, Volume 18, Issue 9Author(s): O. Risi, A. Manfredi, E. Andretta
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Conditions:   Overactive Bladder;   Urinary Incontinence Interventions:   Device: Microcurrents;   Device: Placebo Microcurrents Sponsor:   University of Las Palmas de Gran Canaria Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Geriatrics | Overactive Bladder | Overactive Bladder Syndrome | Urology & Nephrology